Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and.

Business Wire • Nov 25, 2025

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact on weight loss and body composition. Published in Obesity Surgery, a leading international journal dedicated to the treatment of obesity and metabolic disease, results f.

Business Wire • Nov 20, 2025

Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing in bariatric and obesity care. This new partnership draws upon ProSurg Medical's 30-year experience in the Brazilian market and reflects Allurion's commitment to establishing a new standard of care in obesity management focused on metabolically h.

Business Wire • Nov 18, 2025

4 Medical Product Stocks to Watch From a Challenging Industry

The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.

Zacks Investment Research • Nov 17, 2025

Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript

Allurion Technologies Inc. ( ALUR ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Tara Brady Shantanu Gaur - Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Conference Call Participants Joshua Jennings - TD Cowen, Research Division Presentation Operator Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.

Seeking Alpha • Nov 12, 2025

Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights Successfully passed U.S. Food and Drug Administration (“FDA”) Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and no Form 483 issued Completed Premarket Approval (“PMA”) Acceptance and Filing Reviews, entered Substantive.

Business Wire • Nov 12, 2025

Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced it has passed critical milestones in the U.S. Food and Drug Administration (the “FDA”) Pre-Market Approval (“PMA”) process for the Allurion Smart Capsule. In addition, the Company announced it has entered into a transaction with its creditor to exchange all of its outstanding debt and obligations under its Revenue Interest Financ.

Business Wire • Nov 11, 2025

Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 12, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 96.

Business Wire • Nov 6, 2025

Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of the first peer-reviewed study on the consecutive use of the Allurion Smart Capsule, a first of its kind, swallowable, procedure-less weight-loss device. Published in Obesity Surgery, a leading international journal dedicated to the treatment of obesity and metabolic disease, the multicenter, retrospective study demonstrates that two consecu.

Business Wire • Oct 7, 2025

Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held on October 9, 2025 at the Metropolitan Club in New York City. Management will hold one-on-one meetings with investors throughout the day. Investors can register for the conference by contacting their ROTH Capital Partners representative. About Allurion Allurion is.

Business Wire • Sep 30, 2025